Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection

Current Opinion in Immunology

Volumn 14, Issue 4, 2002, Pages 487-494

  Gandhi, Rajesh T ^a   Walker, Bruce D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2;

ANIMAL CELL; ANTIBODY RESPONSE; APOPTOSIS; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; NONHUMAN; REVIEW; SPECIES DIFFERENCE; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; CHRONIC DISEASE; HAPLORHINI; IMMUNITY; IMMUNOLOGY; PATHOGENICITY;

AIDS VACCINES; ANIMALS; CHRONIC DISEASE; HAPLORHINI; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; T-LYMPHOCYTES, CYTOTOXIC; VIREMIA;

EID: 0036668247     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00359-X     Document Type: Review

References (70)

1. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
2. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
3. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
4. Immune reconstitution in patients with HIV infection
5. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
6. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
7. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
8. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
9. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
10. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
11. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy
12. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine
13. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
14. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
15. Immunologic control of HIV-1
16. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
17. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: Evidence for impaired CTL effector function
18. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection
19. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
20. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
21. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
22. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3ζ and CD28, key signaling molecules for T-cell activation
23. Skewed maturation of memory HIV-specific CD8 T lymphocytes
24. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection
25. Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells
26. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes
27. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells
28. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain
29. CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas/FasL death signaling pathway
30. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
31. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
32. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice
33. Viral immune evasion due to persistence of activated T cells without effector function
34. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution
35. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy
36. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
37. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
38. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group
39. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
40. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
41. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation
42. Immune control of HIV-1 after early treatment of acute infection
43. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
44. Control of SIV rebound through structured treatment interruptions during early infection
45. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
46. Immune control of HIV: The obstacles of HLA and viral diversity
47. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes
48. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
49. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
50. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
51. A role for carbohydrates in immune evasion in AIDS
52. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes
53. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
54. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
55. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
56. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
57. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy
58. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
59. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
60. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
61. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
62. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
63. One step forwards, one step back
64. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
65. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
66. Evolution and transmission of stable CTL escape mutations in HIV infection
67. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection
68. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
69. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
70. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF